SCHEMBL661740

SCHEMBL661740

NN1CCS(=O)(=O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18552568 0.89 RAB9A (0.33)
SCHEMBL21389056 0.81
SCHEMBL18552566 0.75
SCHEMBL44722 0.72 RAB9A (0.36)
SCHEMBL2253832 0.69
SCHEMBL209495 0.69
SCHEMBL182685 0.69 HSD17B10 (0.31)
SCHEMBL242394 0.68
SCHEMBL64228 0.68
SCHEMBL12551200 0.67 LMNA (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119039317-A Benzenedinitrogen-doped benzothiophene compound, and preparation method and application thereof 郑州大学 2024-11-29 CN claimed
CN-106397356-B The preparation method of thiomorpholine -1,1- dioxide. HCl, the preparation method of thiomorpholine -1,1- dioxide 郑州原理生物科技有限公司 2019-08-13 CN claimed
EP-4682148-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2026-01-21 EP disclosed
US-20250270201-A1 SUBSTITUTED PYRIMIDINYL HYDRAZIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF ARIGENX THERAPEUTICS CO., LTD. (CN) 2025-08-28 US disclosed
US-20250161318-A1 SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT ABBVIE INC (US) 2025-05-22 US disclosed
WO-2025047408-A1 NUCLEIC ACID PURIFICATION METHOD AND KIT FOR NUCLEIC ACID PURIFICATION 栄研化学株式会社 2025-03-06 WO disclosed
EP-4497747-A1 SUBSTITUTED PYRIMIDINE HYDRAZIDE COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF Arigenx Therapeutics Co., Ltd. (CN) 2025-01-29 EP disclosed
US-20250019364-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2025-01-16 US disclosed
EP-4474383-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2024-12-11 EP disclosed
CN-119039317-A Benzenedinitrogen-doped benzothiophene compound, and preparation method and application thereof 郑州大学 2024-11-29 CN disclosed
US-20240254118-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-08-01 US disclosed
US-4332801-A HYPOTENSIVE; CARDIOVASCULAR DISORDERS CASSELLA AKTIENGESELLSCHAFT (DE) 1982-06-01 US disclosed
US-4328223-A 2-Amino-3a,4,5,6-tetrahydro-perimidine derivatives and their medicinal use in combatting circulatory diseases BAYER AKTIENGESELLSCHAFT (DE) 1982-05-04 US disclosed
EP-0042570-A1 20-Deoxyrosaramicin derivatives, process for their preparation and pharmaceutical compositions containing them SCHERING CORPORATION (US) 1981-12-30 EP disclosed
US-4305939-A HYPOTENSIVE CASSELLA AG (DE) 1981-12-15 US disclosed
US-4254128-A 2-Adamantyl hydrazines and biocidal compositions thereof TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 1981-03-03 US disclosed
US-4237051-A Stereospecific production of 6- or 7-carbon-substituted-β-lactams SCHERING CORPORATION (US) 1980-12-02 US disclosed
EP-0002066-A1 2-Adamantyl hydrazines and pharmaceutical compositions containing them Teva Pharmaceutical Industries Limited (IL) 1979-05-30 EP disclosed
US-3989690-A ANTI-PARASITIC AGENTS ACTIVE AGAINST TRYPANOSOMIDAE LILLY INDUSTRIES, LTD. (EN) 1976-11-02 US disclosed
US-3884913-A 4-(1{40 -Alkyl-5{40 -nitroimidazolyl-2{40 -methylene -imino)-tetrahydro-1,4-thiazine-1,1-dioxides and process for their manufacture HOECHST AG 1975-05-20 US disclosed